ArticlePloS one2011
MicroRNA expression characterizes oligometastasis(es).
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 122 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer
Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy of All Body Locations With the Disease at 3 Months After First Line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer, Prior to Maintenance Therapy
Who cites it
122 citing papers in PubMed, 3 syntheses or guidelines pooled it, 277 citations in OpenAlex.
- Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.Frontiers in medicine · 2026Pooled it
- Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.ESMO open · 2023Pooled it
- A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?World journal of urology · 2019Pooled it
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA oncology · 2020Trial
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.The Lancet. Oncology · 2016Trial
- Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.Nature reviews. Urology · 2026Review
- Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung Cancer.JCO precision oncology · 2026Article
- Insights on Oligometastatic Non-Small-Cell Lung Cancer.Cancers · 2025Review
- Oligometastatic pancreatic cancer: current state of management and emerging therapies.The oncologist · 2025Review
- Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published Data.Cancers · 2025Review
- Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.Journal of gastrointestinal cancer · 2025Review
- A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.Cancers · 2025Review
- Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.JTO clinical and research reports · 2024Review
- The optimal stereotactic body radiotherapy dose with immunotherapy for pulmonary oligometastases: a retrospective cohort study.Journal of thoracic disease · 2024Article
- Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability.Annals of surgical oncology · 2024Review
- Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.Current oncology reports · 2024Review
- Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging.Clinical and translational radiation oncology · 2024Article
- Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases.Frontiers in endocrinology · 2024Article
- Isolated pulmonary metastases in pancreatic ductal adenocarcinoma: a review of current evidence.Cancer biology & therapy · 2023Review
- Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program.International journal of surgery protocols · 2023Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCancer staging and treatment presumes a division into localized or metastatic disease. We proposed an intermediate state defined by ≤ 5 cumulative metastasis(es), termed oligometastases. In contrast to widespread polymetastases, oligometastatic patients may benefit from metastasis-directed local treatments. However, many patients who initially present with oligometastases progress to polymetastases. Predictors of progression could improve patient selection for metastasis-directed therapy.
methodsHere, we identified patterns of microRNA expression of tumor samples from oligometastatic patients treated with high-dose radiotherapy.
resultsPatients who failed to develop polymetastases are characterized by unique prioritized features of a microRNA classifier that includes the microRNA-200 family. We created an oligometastatic-polymetastatic xenograft model in which the patient-derived microRNAs discriminated between the two metastatic outcomes. MicroRNA-200c enhancement in an oligometastatic cell line resulted in polymetastatic progression.
conclusionsThese results demonstrate a biological basis for oligometastases and a potential for using microRNA expression to identify patients most likely to remain oligometastatic after metastasis-directed treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.